Paper334223
Nomifensine in Parkinson's disease.
Bedard P and 2 others. Br J Clin Pharmacol, 1977. Cited by 28 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Nomifensine in Parkinson's disease. Papers, record 334223. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/334223
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Isoquinolines | Major topic |
| Nomifensine | Major topic |
| Parkinson Disease | Major topic |
| Adult | |
| Aged | |
| Carbidopa | |
| Clinical Trials as Topic | |
| Drug Therapy, Combination | |
| Female | |
| Humans | |
| Levodopa | |
| Male | |
| Middle Aged | |
| Placebos | |
| Trihexyphenidyl |
Source PubMed
References12
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 796,415 | Nomifensine in parkinsonism. | J Neurol Neurosurg Psychiatry | 1976 | https://conductscience.org/library/papers/796415 | PubMed |
| 2 | 778,880 | Psychiatric symptoms during l-dopa therapy for Parkinson's disease and their relationship to physical disability. | Psychol Med | 1976 | https://conductscience.org/library/papers/778880 | PubMed |
| 3 | 4,375,258 | Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum. | Naunyn Schmiedebergs Arch Pharmacol | 1974 | https://conductscience.org/library/papers/4375258 | PubMed |
| 4 | 4,152,974 | Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatum. | J Pharm Pharmacol | 1974 | https://conductscience.org/library/papers/4152974 | PubMed |
| 5 | 4,396,660 | Comparative studies of various amphetamine analogues demonstrating different interactions with the metabolism of the catecholamines in the brain. | Eur J Pharmacol | 1971 | https://conductscience.org/library/papers/4396660 | PubMed |
| 6 | 4,147,437 | A study of the role of catecholamines in the response to various central stimulants. | Eur J Pharmacol | 1973 | https://conductscience.org/library/papers/4147437 | PubMed |
| 7 | 7,659 | The effects of blocking catecholamine uptake on amphetamine-induced circling behaviour in mice with unilateral destruction of striatal dopaminergic nerve terminals. | J Pharm Pharmacol | 1976 | https://conductscience.org/library/papers/7659 | PubMed |
| 8 | 4,441,422 | Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes. | Biochem Pharmacol | 1974 | https://conductscience.org/library/papers/4441422 | PubMed |
| 9 | 4,740,695 | 8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant. | Arzneimittelforschung | 1973 | https://conductscience.org/library/papers/4740695 | PubMed |
| 10 | 1,097,600 | Amphetamines in the treatment of Parkinson's disease. | J Neurol Neurosurg Psychiatry | 1975 | https://conductscience.org/library/papers/1097600 | PubMed |
| 11 | 1,098,084 | Nomifensine: a potent dopaminergic agonist of antiparkinson potential. | Psychopharmacologia | 1975 | https://conductscience.org/library/papers/1098084 | PubMed |
| 12 | 986,308 | Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984). | Eur J Pharmacol | 1976 | https://conductscience.org/library/papers/986308 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 33,824,605 | Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence. | J Exp Pharmacol | 2021 | https://conductscience.org/library/papers/33824605 | PubMed |
| 32,860,561 | The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. | J Neural Transm (Vienna) | 2020 | https://conductscience.org/library/papers/32860561 | PubMed |
| 25,810,948 | Monoamine reuptake inhibitors in Parkinson's disease. | Parkinsons Dis | 2015 | https://conductscience.org/library/papers/25810948 | PubMed |
| 22,233,519 | A searchable cross-platform gene expression database reveals connections between drug treatments and disease. | BMC Genomics | 2012 | https://conductscience.org/library/papers/22233519 | PubMed |
| 21,562,283 | Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. | J Neurosci | 2011 | https://conductscience.org/library/papers/21562283 | PubMed |
| 15,954,137 | Antidepressant studies in Parkinson's disease: a review and meta-analysis. | Mov Disord | 2005 | https://conductscience.org/library/papers/15954137 | PubMed |
| 9,467,687 | Depression in Parkinson's disease. Pharmacological characteristics and treatment. | Drugs Aging | 1998 | https://conductscience.org/library/papers/9467687 | PubMed |
| 911,653 | A profile of nomifensine. | Br J Clin Pharmacol | 1977 | https://conductscience.org/library/papers/911653 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/334223
GET https://conductscience.org/api/papers/v1/334223/authors